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Recombinant AhpC antigen from Mycobacterium bovis boosts BCG-primed
immunity in mice
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Abstract: Tuberculosis (TB) is still one of the most common infectious diseases around the world despite the widespread use of BCG
(bacille Calmette-Guerin) strain of Mycobacterium bovis as a vaccine. This vaccine does not always protect people from TB, and, thus,
new effective vaccines or vaccination strategies are being investigated. In this study, alkyl hydroperoxide reductase (AhpC) from M.
bovis was evaluated as a new candidate vaccine antigen against TB in BALB/c mice model. The ahpC gene was amplified from M.bovis
genome, cloned, and expressed in Escherichia coli. Vaccine antigen AhpC was formulated with Montanide ISA 61 VG, an oil-based
emulsion adjuvant. Both IgG and IL-12 responses were observed in mice after administering the formulation both as a subunit vaccine
alone and also as a booster vaccine for BCG immunization. However, a long-lasting response was observed when AhpC formulation
was used as a booster (for BCG-primed immunization) as compared to being used as a subunit vaccine alone. In short, these findings
suggested that AhpC has the potential to be used as a booster vaccine candidate for BCG-primed immunization.
Key words: Subunit vaccine, tuberculosis, prime-boost vaccination, recombinant protein

1. Introduction
Tuberculosis (TB) is an infectious disease that is primarily
caused by the inhalation of particles containing bacilli
within the Mycobacterium tuberculosis complex (MTBC)
(Kanipe and Palmer, 2020). While M. tuberculosis mainly
infects the human host, the primary causative agent for TB
in the family Bovidae is M. bovis (Rodriguez-Campos et
al., 2014). The susceptibility of humans to TB caused by
M. bovis is attributed to its zoonotic character (Michel et
al., 2010). In addition to person-to-person transmission
(Evans et al., 2007; Sunder et al., 2009)., M. bovis is also
transmitted in humans by consumption of unpasteurized
or contaminated dairy products or inhalation of aerosols
containing bacillus (Grange, 2001).
Since 1931, M. bovis Bacillus Calmette-Guérin (BCG)
vaccine has been used as the only licensed vaccine against
TB. Although BCG vaccine is widely used worldwide,
high variability in its efficacy (0%–80%), ineffectiveness
against pulmonary TB in adults (Colditz, 1994), and safety
risks due to the possibility of mutation to its virulent form
(Fatima et al., 2020) clearly demonstrate the need for a
more effective vaccine protecting against all forms of TB
in all age groups. Currently, several vaccines are under

clinical trials either as potential alternatives for BCG or as
booster vaccines (Whitlow et al., 2020).
Data obtained from virulence gene identification
studies play an essential role both in the discovery of new
drug targets and in the development of novel TB vaccine
candidates. The virulence factor proteins of M. bovis inhibit
the macrophages’ antimicrobial attacks and enhances the
resistance of the bacilli against the first immune attack
of the macrophages (via oxidative and nitrosative stress
responses, phagosome arresting, and apoptosis inhibition)
(Forrellad et al., 2013). A typical example of this is alkyl
hydroperoxide reductase C (Rv2428, AhpC), a member of
the peroxiredoxin family, that catalyzes the detoxification
reaction of organic peroxides into less reactive derivatives.
Thus, AhpC can protect the microbial pathogen against
both oxidative and nitrosative stresses (EcheverriaValencia et al., 2018).
Sequence similarity of ahpC genes from different
Mycobacterium species, including M. bovis, M. tuberculosis,
M. ulcerans, M. africanum, M. smegmatis, M. sinense, and
M. leprae was shown in the paper of Wong et al. (2013). The
protective effect of AhpC against oxidative stress responses
of the host immune cells and correlation between ahpC
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gene expression and bacterial virulence were extensively
investigated by other researchers (Wilson and Collins,
1996; Wilson et al., 1998). Verma et al. (2021) revealed
kasA and ahpC genes as potential drug targets due to their
roles in drug resistance. Considering these features of the
AhpC, it was thought that it could be both a vaccine and
also a drug candidate.
In this study, ahpC gene was amplified from M.bovis and
heterologously produced in E.coli BL21(DE3) expression
system. Then, purified recombinant AhpC protein was
formulated with an oil-based adjuvant. We investigated
the immunostimulatory effect of the antioxidant enzyme
AhpC both as a subunit vaccine alone and a booster
vaccine after BCG prime immunization in BALB/c mice
groups.
2. Materials and methods
2.1. Bacterial strains, media, and plasmids
Escherichia coli strains DH5α (Novagen, Germany) and
BL21 (DE3) (ATCC, USA) were used for cloning and
expression of the gene ahpC, respectively. LB Broth with
agar (Miller) and LB Broth (Miller) media were used
for the cultivation of E.coli strains. Isolated and purified
genomic DNA of M. bovis (ATCC 35743, GenBank
CP003494.1, USA) was kindly provided by Assoc. Prof. Dr.
Alpaslan Alp (Hacettepe University Faculty of Medicine,
Department of Medical Microbiology, Ankara, Turkey).
The pGEMT Easy (Promega, USA) and pET28a(+)
(Novagen, Germany) plasmids were used for gene cloning
and recombinant protein expression, respectively. Protino
Ni-TED kit (Macherey-Nagel, Germany) was used to
purify His-tagged recombinant protein.
2.2. PCR amplification of ahpC gene
The genomic DNA of M. bovis was used as the template
for amplification of ahpC gene (588 bp). The nucleotide
sequence corresponding to ahpC gene was amplified
using polymerase chain reaction (PCR) with the
following two pairs of gene-specific primers, ahpCF: 5’–
ggatccatgccactgctaaccattg-3’ (BamHI site underlined)
and ahpCR: 5’-aagcttggccgaagccttgag - 3’ (HindIII site
underlined). All chemical and biological reagents were
purchased from ThermoScientific. PCR mix composed of
2.5 mM MgCl2, 0,2 µM of primers, 1 ng template DNA,
0,6 mM dNTP mix (Cat. No. R0192), 1 × Taq buffer (with
KCl, without MgCl2) and 0,1 U Taq DNA polymerase (Cat.
No. EP402) was prepared in a total volume of 25 µL. The
cycling program was set as 94 °C for 10 min, 30 cycles of
amplification (94 °C for 1 min, 52 °C for 30 s, 72 °C for 1
min), and at 72°C for 10 min. PCR products were analyzed
by electrophoresis using 1% (w/v) agarose gel.
2.3. Construction of recombinant plasmids
pGEMT Easy Vector System (Promega, WI, USA) was
used for the ligation of PCR products. The ligation
reaction was performed according to the instructions of
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the manufacturer, and plasmids transformed into E. coli
DH5α. The pGEMT-ahpC product was verified by doubledigestion with BamHI and HindIII enzymes. Afterward,
ahpC gene was cloned in multiple cloning site between
BamHI and HindIII in expression plasmid, pET-28a (+),
which encodes for the 6xHis tag. The resulting recombinant
plasmid was named pET-ahpC and was introduced in
E.coli DH5α. The recombinant bacteria were screened via
restriction enzyme digestion of plasmids and PCR. pETahpC was sequenced by Sanger sequence analysis method
(Sentebiolab, Turkey)
(Supplemental
information).
pET-ahpC
was
subsequently transformed into the host E. coli BL21(DE3)
competent cells (Novagen) for recombinant protein
expression.
2.4. Expression and purification of recombinant AhpC
Expression and purification of recombinant AhpC
(rAhpC) were performed as described by Okay et al.,
(2012). E. coli BL21 (DE3) cells carrying pET-ahpC was
grown in Luria Broth (LB; Merck, Germany) supplemented
with kanamycin (30 µg/mL). When OD600 value of culture
reached 0.5, isopropyl-β-D-galactopyranoside (IPTG;
Sigma, Germany) was added to induce recombinant
protein expression (1 mM final concentration). Incubation
was carried out at 37 °C for 4 h in a shaker incubator at 200
rpm. Expression host cells were collected by centrifugation
(5000 g for 5 min, at 4 °C). Subsequently, the harvested
cells were resuspended in LEW buffer (Lysis-EquilibrationWashing buffer; 50 mM NaH2PO4, 300 mM NaCl, 8 M
urea, pH 8.0). Next, cells were lysed using an ultrasonic
probe (Bandelin-Sonoplus, Germany) at 60% amplitude,
10 s pulses at six intervals. Cellular debris was removed
by centrifugation, and the supernatant containing
recombinant protein was collected. Purification of the
protein was performed by applying the supernatant to a
Ni-NTA affinity column (Protino Ni-TED 2000 packed
columns, Macherey–Nagel, Germany) according to the
supplier’s instructions. Eluted proteins were concentrated
by Amicon ultrafiltration device (Merckmillipore, USA),
sterilized through a 0.2 µm membrane filter, and stored at
–20 °C until use. Bradford’s method (1976) was used to
quantify the recombinant protein.
2.5. Characterization of recombinant AhpC
The protein was further subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS–PAGE)
and Western-blotting to analyze the expression. Briefly,
a purified protein sample was run at the rate of 4%–12%
SDS-polyacrylamide gels (Laemmli, 1970). Coomassie
Blue R-250 staining protocol was performed for one of
the gels, and the other was transferred to nitrocellulose
membrane (0.45 µm) by processing via a modified Towbin
method (1979). The anti rAhpC antibody obtained from
the 60th-day serum of mice vaccinated with rAhpC, at
a dilution factor of 1:400 (v/v) was used as the primary
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antibody. Alkaline phosphatase (AP)-conjugated antimouse IgG (Sigma, Germany) was used as the secondary
antibody (at a dilution of 1:20.000 (v/v)). To visualize
protein bands on nitrocellulose membrane, AP Conjugate
Substrate Kit (Bio-Rad, CA, USA) was applied.
2.6. Preparation of vaccine formulations
A 1 mg/mL rAhpC stock solution was prepared in PBS.
The antigen (rAhpC) solution and adjuvant (Montanide
61VG, Seppic) components were mixed at a ratio of 2:3
(v/v) under aseptic conditions by vortexing for 2 mins.
Prior to use, the sterility of prepared vaccine formulations
was tested using aerobic culture on LB-agar incubated at
37 °C for 48 h.
2.7. Animals and vaccination
6–8 week old female BALB/c mice were immunized in
animal experiments. Animal experiments were performed
under the approval of the Ethics Committee on Animal
Experimentation, Hacettepe University, Turkey (No:
2020/08-16). Animals were immunized subcutaneously
in groups of six with one of the following treatment
conditions:
-Group A (n = 6): Adjuvant control group; immunized
with 250 µL PBS – ISA 61VG mixture (2:3 v/v, administrated
at day 0 and 15).
-Group B (n = 6): BCG control group; immunized
with 0.1 mL, 5x106 CFU BCG vaccine (Serum Institute of
Day 0

Groups
Group A (n=6) Adjuvant

Administration

India), given once (at day 0) and injected with 250 µL of
PBS two times (administrated at day 15 and 30).
-Group C (n = 6): BCG Prime – ISA 61VG Boost
group; immunized with 0.1 mL prime BCG with 5x106
CFU, given once (at day 0) and boosted with 250 µL total
volume of ISA 61VG (administrated at day 15 and 30).
-Group D (n = 6): Adjuvanted rAhpC group;
immunized with 250 µL purified rAhpC formulated with
ISA 61VG (2:3, v/v, administrated at day 0 and 15).
-Group E (n = 6): BCG Prime – AhpC Boost group;
immunized with 0.1mL prime BCG (5x106 CFU), given
once (at day 0) and boosted with 250 µL purified rAhpC
formulated with ISA 61VG (2:3, v/v, administrated at day
15 and 30).
The tail vein of mice was chosen for the collection of
blood samples at day 0, 15, 30, 45, and 60. The collected
serum samples were stored at –20 °C until use. Mice
were euthanized via cervical dislocation at day 60. The
immunization schedule and blood collection times of the
groups are illustrated in Figure 1.
2.8. Detection of antibody response
AhpC-specific IgG levels were measured by enzymelinked immunosorbent assay (ELISA). 96-well plates were
coated with rAhpC protein (1 μg/well). Sera collected from
vaccinated mice were used as the primary antibody. Twofold serial dilutions of primary antibodies (from 1:50 to
1:6400, v/v) were applied in plates in duplicates. Alkaline

Day 15

Administration

blood collection
blood collection
adjuvant administration adjuvant administration

Day 30

Administration

Day 45

Day 60

Administration

Administration

blood collection

blood collection

blood collection
euthanasia

blood collection
PBS administration

Group B (n=6)
BCG prime - PBS Boost

blood collection
BCG administration

blood collection

blood collection
euthanasia

Group C (n=6)
BCG prime – Adjuvant
Boost

blood collection
blood collection
blood collection
blood collection
BCG administration adjuvant administration adjuvant administration

blood collection
euthanasia

Group D (n=6)
AhpC (adjuvanted)

blood collection
AhpC administration

blood collection
AhpC administration

blood collection

blood collection

blood collection
euthanasia

Group E (n=6)
BCG prime - AhpC
(adjuvanted) Boost

blood collection
BCG administration

blood collection
AhpC administration

blood collection
AhpC administration

blood collection

blood collection
euthanasia

blood collection
PBS administration

Figure 1. Schematic illustration of immunization schedule. Blood samples were collected just before vaccine administration at days
0, 15, and 30.
Abbr. PBS, phosphate buffered saline.
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phosphatase-conjugated anti-mouse IgG (Sigma, USA)
was used as a secondary antibody at a dilution factor of
1:1000 (v/v). The AP Conjugate Substrate Kit was used as a
colorimetric reagent (Bio-Rad, USA). Optical density was
measured at 405 nm.
2.9. IL-12 assay
Mouse IL-12 ELISA Total Kit (Thermo Scientific) was
used according to the supplier’s instructions to measure
the cellular immune response in the vaccinated mice.
The sera collected from the vaccinated mice were used as
the primary antibody, and the level of serum IL-12 was
calculated via a standard curve.
2.10. Statistical analysis
ELISA data were analyzed by using the Graphpad Prism
8 software using two-way analysis of variance (ANOVA)
and a posthoc test (Tukey’s test). P values < 0.05 were
considered as significant.
3. Results
3.1. Cloning of ahpC gene
The ahpC gene from M. bovis (588 bp, GenBank
CP003494.1, location: 2400625 .. 2401212) was successfully
amplified (Figure 2). Subsequently, the ahpC gene was
cloned in pGEM-T Easy vector system and pET-28a(+) for
gene amplification and recombinant protein purification,
respectively.
3.2. SDS-PAGE and Western blot analyses of rAhpC
protein
pET-28a(+) vector encoding ahpC was transformed
into E.coli BL21(DE3) for rAhpC production. rAhpC
produced in E.coli was purified using nickel columns.
The molecular weight (MW) of the rAhpC (including

Figure 2. Agarose gel image of ahpC gene was amplified by PCR
from M.bovis genome.
M: DNA marker (G571A, Promega); 1,2: PCR amplified ahpC; 3:
Negative control PCR tube.
Dashed arrows show the expected amplicon size for the AhpC
gene (588 bp, GenBank CP003494.1, location: 2400625 ..
2401212 ).
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His-tags) was predicted as 22.389 kDa using a web-based
tool (ProtParam, https://web.expasy.org/protparam). The
observed MW of the rAhpC protein on SDS-PAGE was
approximately 25 kDa (Figure 3a). Protein-specific sera
were used as primary antibody in Western blot analysis.
Antibodies in sera also bind ~50 kDa dimerized rAhpC
protein (Figure 3b).
3.3. Humoral immune response against AhpC
Antibody-mediated immune responses depend on
different functions of multiple classes of antibodies (i.e,
IgM, IgA, IgG, and IgE). Among them, IgG is known
with its antigen specific high affinity and also its ability
for neutralization of the infectious pathogens as well as
its Fc-mediated effector functions. On the other hand, its
characteristics such as abundance and long half-life time
in blood and also interaction with differentiated memory
B cells render immunoglobulin G as a good indicator for
humoral immune responses (Galipeau et al., 2020).
In this study, quantitative detection of the humoral
immune response against AhpC protein was tested using
ELISA method. The total IgG level in collected sera of mice
groups was evaluated at day 0, 15, 30, 45, and 60 (Figure 4)
using two-way ANOVA and Tukey’s test (Table 1).
All vaccination regimens were well tolerated by the
mice groups. In Group A (adjuvant ISA 61 VG vaccination
group), the anti-AhpC IgG was not detected until day
60. All other groups, on the other hand, showed a AhpC
specific IgG response from day 30 indicating that BCG
or adjuvanted AhpC vaccination requires at least 30
days to induce anti-AhpC antibodies. Introduction of
second second dose adjuvanted AhpC elicited antibody
production in Group D (adjuvanted rAhpC group), but it
was not as high as in Group E (BCG prime – AhpC boost
group). At day 45 and 60, the serum of mice in Group
C (BCG Prime – ISA 61VG boost group) or Group B
(BCG control Group) retained anti-AhpC IgG antibodies.
Likewise, at day 45 and 60, increased anti-AhpC IgG levels
were detected in Group D (Adjuvanted AhpC group) and
Group E (BCG prime – AhpC boost group). The results
indicate that administering the second dose of AhpC as
a booster increases the anti-AhpC level up to 60 days
(Figure 4).
Our results showed that vaccination with adjuvanted
AhpC alone was more effective than ISA 61 VG alone
(Group A vaccination group) and BCG alone (Group B
vaccination group) at the end of 60 days (p < 0.001 and p
< 0.01, respectively, Table 1). However, when adjuvanted
AhpC was used as a booster to prime BCG vaccine, a more
potent and sustainable humoral immune response was
induced during the 60-day period (Figure 4 Table 1).
In Group E, single-dose adjuvanted AhpC vaccination
after BCG prime immunization induced a stronger
humoral response compared to Group D, which was
immunized with two doses of adjuvanted AhpC (p < 0.001,
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Figure 3. Gel images of SDS-PAGE analyis by Coomassie blue staining (A) and Western blot (B). The primary antibodies
used in WB were obtained from the 60th day serum of AhpC vaccination group (Group D).
M: Prestained protein ladder (Bio-Helix, PM007),
1: Lysate of E.coli carrying pET-ahpC (IPTG non-induced),
2: Lysate of E.coli carrying pET-ahpC (IPTG-induced),
3: Flow-through fraction,
4-5: First and second washing fractions, respectively,
6-7: First and second elutions of recombinant AhpC protein, respectively.

Figure 4. Measured OD405 values of total serum IgG in BALB/c mice. Samples were diluted by a dilution factor of 1:200.
PBS was used as blank solution, and measured OD405 value of PBS has been subtracted from all absorbances.
Abbr. PBS; phosphate buffered saline.
Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS boost (Navy blue); Group C: BCG Prime – ISA 61VG
Boost (red); Group D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC Boost (green).

Figure 4, Table 1). Moreover, injection of a second booster
dose of adjuvanted AhpC in Group E increased the serum
antibody level more (at day 45).
In a nutshell, anti-AhpC IgG antibodies were induced
both with AhpC vaccine alone and BCG primed – AhpC
booster vaccine regimens at day 60.

3.4. Cellular immune responses induced by vaccinations
The change in serum IL-12 level in the vaccination groups
at day 0, 15, 30, 45, and 60 (Figure 5) was evaluated (Table
2).
In all mice groups, the srum IL-12 was at basal level
at day 0. At day 15, an increase in serum IL-12 level was
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Table 1. Analysis of variance (ANOVA) for serum IgG levels in
BALB/c mice groups.
Vaccination Groups

Day 0 Day 15 Day 30 Day 45 Day 60

Group A – Group B

NS

NS

*

***

****

Group A – Group C

NS

NS

**

****

****

Group A – Group D

NS

NS

**

**

***

Group A – Group E

NS

NS

****

****

****

Group B – Group C

NS

NS

*

*

***

Group B – Group D

NS

NS

**

*

**

Group B – Group E

NS

NS

****

****

****

Group C – Group D

NS

NS

**

*

**

Group C – Group E

NS

NS

****

****

****

Group D – Group E

NS

NS

***

****

****

Note: PBS measurements were subtracted from those of vaccination
groups. Day 0 is considered as the point of pre-immunization. *p <
0.05. **p < 0.01. ***p < 0.001. ****:p < 0.0001; NS: not significant.
Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS
boost (Navy blue); Group C: BCG Prime – ISA 61VG Boost (red); Group
D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC Boost
(green).

Figure 5. Serum IL-12 concentrations of BALB/c mice at different time intervals.
Abbr. Conc; concentration.
Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS boost (Navy blue); Group C: BCG Prime – ISA 61VG Boost
(red); Group D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC Boost (green).

observed in all groups with the highest value measured
in adjuvanted AhpC treated group. The adjuvant effect of
booster ISA 61 VG is clearly witnessed (at day 30, 45 and
60) in the differences in serum IL-12 level between Group
B (BCG control group) and Group C (BCG prime – ISA 61
VG boost group). The highest IL-12 levels were achieved
in Group E after first AhpC bosster as well as after second
AhpC booster. At day 60, a decrease in serum IL-12 was
observed in all groups, yet still, the highest serum IL-12
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level was measured in Group E (BCG prime – AhpC bosst
group) (Figure 5).
At day 15, although an increase in serum IL-12 level
was observed in all groups after the first vaccination, the
highest titer was realised in adjuvanted AhpC vaccination
group (Group D). On the contrary, an increase in serum
IL-12 titers was seen in all groups except adjuvanted AhpC
vaccination group (Group D) at day 30. Interestingly, a
second booster dose of adjuvanted AhpC led to a decrease
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Table 2. Analysis of variance (ANOVA) for serum IL-12 levels in
BALB/c mice groups.
Vaccination Groups Day 0 Day 15 Day 30 Day 45 Day 60
Group A – Group B

NS

****

****

****

****

Group A – Group C

NS

****

****

****

****

Group A – Group D

NS

****

****

****

****

Group A – Group E

NS

****

****

****

****

Group B – Group C

NS

NS

**

**

****

Group B – Group D

NS

****

****

****

****

Group B – Group E

NS

NS

****

****

****

Group C – Group D

NS

****

***

*

NS

Group C – Group E

NS

NS

****

****

****

Group D – Group E

NS

****

***

****

****

Note: Day 0 is considered as the time point of pre-immunization. *p
< 0.05. **p < 0.01. ***p < 0.001. ****:p < 0.0001; NS: not significant.
Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime –
PBS boost (Navy blue); Group C: BCG Prime – ISA 61VG Boost (red);
Group D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC
Boost (green).

in serum IL-12 concentration, unlike the first booster
dose, which raised the IL-12 levels. At days 30, 45, and
60, Group C (BCG prime – ISA 61 VG boost group) had
relatively higher levels of IL-12 as compared to Group B
(BCG control group) (p < 0.01, p < 0.001 and p < 0.0001,
respectively) due to the adjuvant effect of Montanide
ISA 61 VG. At days 45 and 60, the serum IL-12 level in
adjuvanted AhpC vaccination (Group D) was less than
Group E (BCG prime – AhpC boost group).
In summary, adjuvanted AhpC did not elicit strong
immune responses when it was administrated alone;
however, an immunostimulation enhancer effect was
observed when it was used as a booster vaccine in BCG
prime immunized mice.
4. Discussion
Currently, BCG is widely used in many countries in the
childhood vaccination program to prevent severe forms of
TB in children. However, BCG vaccination is considered
not sufficient aginst TB infection in adults (World Health
Organization, 2020). Therefore, efforts in the prevention
of TB are mainly focused on the development of new
vaccines, new drugs, or innovative treatment strategies.
Currently, various new drugs, vaccines, and combination
regimens are under investigation in clinical trials.
In this study, a new recombinant vaccine formulation
composed of AhpC and an oil-based adjuvant Montanide
ISA 61 VG was administered to mice as a subunit vaccine
alone and as a booster after BCG-prime vaccination.

Although AhpC is a protein with a molecular wight of
~25 kDa, we observed two distinct bands (~25 kDa and
~50 kDa) in SDS-PAGE as shown in the study of O’Riordan
et al. (2012). The band of 50 kDa was due to the possible
dimerization of AhpC between two cysteine sulfhydryls in
protein structure (Hillas et al., 2000; Chauhan and Mande,
2002). Two bands at 25 and 50 kDa were also detected
in Western blot, which belongs to AhpC and its dimer
form, respectively. Although this lane was lysate of nonIPTG-induced E.coli BL21(DE3) harboring pET-ahpC,
the protein bands were probably a result of phenomenon
known as the leaky expression of T7promoter – T7RNA
polymerase system (McCutcheon, 2018).
Disperse systems, chemical or biological molecules can
be used as adjuvants in order to enhance the immunogenicity
of an antigen. Studies have been conducted to evaluate
adjuvant’s potential use in the vacines against infectious
diseases, cancer, and autoimmune diseases (Shah et al.,
2015). Montanide adjuvant system includes mineral
or non-mineral oils, a mannitol-based surfactant, and
purified oleic acid from vegetable origin (Jang et al., 2010).
They are classified as emulsions, micro-emulsions, and
polymeric gels according to their preparation technology
(Seppic, 2017). Montanide ISA 61 VG adjuvant is a readyto-use mineral oil-based stable w/o emulsion formulation,
and it induces high-level and long-lasting immune
responses in animals (Khorasani et al., 2016).
Since subunit vaccines contain only the antigenic parts
of the pathogen, replication in the host is not possible.
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Therefore, they have advantages in terms of safety
considerations. On the other hand, certain drawbacks
such as the requirement of multiple doses and coadministration of adjuvant(s) to elicit a vigorous humoral
or cellular immune response against the antigen(s) of
interest hinders the use of vaccines (Hansson et al., 2000).
In this study, no anti-AhpC antibodies were detected in the
adjuvanted AhpC vaccination group (Group D) 15 days
after the first dose, but, rather, the anti-AhpC antibodies
were detected after the second dose adjuvanted AhpC
administration (boost injection). At day 60 of the study,
anti-AhpC antibodies reached maximum levels 4 weeks
after booster injection, also reported by O’Riordan et al.
(2012). Although more studies are required for a better
understanding of the mechanism of action of adjuvants
used in vaccine formulations, it is believed that water-inoil emulsion-based adjuvants induce local inflammation
and increase the recruitment and activation of antigenpresenting cells (Leroux-Roels, 2010). Enhancer effect of
ISA 61 VG adjuvant on antibody responses was reported by
others (İz et al., 2018). We observed this effect also in our
study by comparing the results of Group B (BCG control
group) and Group C (BCG prime – ISA 61 VG boost
group). First and second booster doses of ISA 61 VG given
to BCG-prime vaccinated mice enhanced the production
of anti-AhpC IgG at day 30 and 45, respectively (Table 1, p
< 0.05). At the end of immunization (day 60), serum antiAhpC antibody level of Group C was higher than Group B
(Table 1, p < 0.001).
The importance of cell-mediated responses for immune
protection against intracellular pathogens such as M.
tuberculosis is well known. Cytokines such as interferon-γ
(IFN-γ), tumor necrosis factor α (TNF-α), and interleukin
12 (IL-12) play a vital role in protective cell-mediated
immune response against TB disease (Kaufmann, 2008).
Therefore, the selection of appropriate adjuvant is a critical
step for subunit vaccine formulations, since either humoral
or cellular immune responses can be induced depending
on the type of adjuvant used in the vaccine formulation.
In addition to stimulating the antibody responses,
Montanide ISA 61 VG adjuvant also has a strong inducer
effect on cellular immune response (Ibrahim et al., 2015).
Our observation of serum IL-12 levels of the mice groups
revealed an outcome that is different from the results of
IgG responses. Unlike with the antibody response, which
constantly increased up to day 60, the serum IL-12 level
decreased after second booster doses at day 30 (only for
Group D), day 45 (for all groups except for Group E),
and day 60 (for all groups). This observation could be
attributed to a negative feedback loop, due to the release
of immunoregulatory cytokines or imbalance between
regulatory and effector T cell subsets, as suggested by Begg
et al. (2019). Nevertheless, the rise in serum IL-12 level
in Group A demonstrates the cellular immune response
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enhancing ability of the adjuvant. Between Group B and
Group C, the latter had relatively higher levels of serum
IL-12 at days 30, 45, and 60.
A study conducted by Karonga Prevention Trial
Group to evaluate the effect of revaccination with BCG
in humans has revealed that a second BCG vaccination
could not provide any protection against tuberculosis.
It was suggested that boosting of immune responses in
BCG-primed vaccinations could possibly enhance BCG
immunity (Valdés et al., 2019). In this light, Yang et al.
(2016) showed in their study that the use of BCG prime
– subunit recombinant protein vaccine immunization
strategy could enhance the cellular immune response in
mice. Different boosting strategies and the importance of
prime – boost immunization in vaccination against TB
were well reviewed by Dalmia and Ramsay (2012). Overall,
immune response against M. tuberculosis by a two-stage
vaccination regimen based on priming with BCG and
boosting with the most effective subunits seems to be the
most promising approach. When the effect of adjuvanted
AhpC used as subunit vaccine alone was compared with
AhpC used as a booster to BCG prime in BALB/c mice, it
was realised that a single dose adjuvanted AhpC could not
induce anti-AhpC antibody response unless supplemented
with a second dose booster. However, a single dose AhpC
as a booster after BCG – prime vaccination elicited higher
IgG responses.
When it comes to cellular immune response, it was
observed that group treated with a single dose of adjuvanted
AhpC induced a stronger IL-12 response as compared to
adjuvant and BCG vaccination groups. But afterwards,
second dose adjuvanted AhpC administration caused a
decrease in serum IL-12 level. Based on this observation,
adjuvanted AhpC vaccination could be said to induce the
highest level of IL-12. However, a more robust profile for
strong humoral responses was obtained in BCG prime –
AhpC boost vaccination group (Group E), suggesting that
‘BCG prime – AhpC boost’ vaccination could be a useful
strategy for the development of a TB vaccine against
tuberculosis disease. Further bacterial challenge studies
are needed to evaluate the immunoprotective effect of
BCG prime – AhpC boost vaccination strategy against
tuberculosis disease caused by virulence strain of M. bovis
or M. tuberculosis.
In this study, we evaluated the effect of antioxidant
enzyme, AhpC, on humoral and cellular immune
responses in BALB/c mice for a period of 60 days. A new
recombinant vaccine formulation composed of AhpC
protein antigen, and an oil-based adjuvant Montanide
ISA 61 VG was administered to mice as a subunit vaccine
formulation alone and as a booster for BCG – prime
vaccination. Based on our results, the BCG prime – AhpC
boost vaccination strategy prolonged both humoral and
cellular immune response. It can be concluded that AhpC,
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an antioxidant protein, is a promising subunit vaccine
antigen when used in BCG prime-AhpC protein boost
vaccination strategy against TB.
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Supplemental Information

Sanger Sequence Analysis of pET-ahpC:
GGCCCTTCCCTCCTCCAGCTCACCGCTCTCATCGGCGGTGACCTGTCCAAGGTCGACGCCA
AGCAGCCCGGCGACTACTTCACCACTATCACCAGTGACGAACACCCAGGCAAGTGGCGG
GTGGTGTTCTTTTGGCCGAAAGACTTCACGTTCGTGTGCCCTACCGAGATCGCGGCGTTCA
GCAAGCTCAATGACGAGTTCGAGGACCGCGACGCCCAGATCCTGGGGGTTTCGATTGACA
GCGAATTCGCGCATTTCCAGTGGCGTGCACAGCACAACGACCTCAAAACGTTACCCTTCC
CGATGCTCTCCGACATCAAGCGCGAACTCAGCCAAGCCGCAGGTATCCTCAACGCCGACG
GTGTGGCCGACCGCGTGACCTTTATCGTCGACCCCAACAACGAGATCCAGTTCGTCTCGG
CCACCGCCGGTTCGGTGGGACGCAACGTCGATGAGGTACTGCGAGTGCTCGACGCCCTCC
AGTCCGACGAGCTGTGCGCATGCAACTGGCGCAAGGGCGACCCGACGCTAGACGCTGGC
GAACTCCTCAAGGCTTCGGCCAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCAC
TGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGA
GCAATAAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGA
AAGGAGGAACTATATCCGGATTGGCGATGGGGACGCGCCATGTAACGGCGCTATAAACG
CGGCAGGTGT
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BLAST analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi#1765) of Sanger sequenced pET-ahpC.
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